CDP-choline Treatment in ATS Users

Cytidine-5'-Diphosphate-choline Treatment in Amphetamine Type Stimulant-using Adolescents

This study is a 12-week, randomized, double-blind, placebo-controlled trial of cytidine-5'-diphosphate choline in amphetamine-type stimulants-using adolescents.

This study is a 12-week, randomized, double-blind, placebo-controlled trial of cytidine-5'-diphosphate choline (CDP-choline) in amphetamine-type stimulants-using adolescents. Multi-level assessments will be performed to determine whether CDP-choline administration with supportive psychotherapy, compared to placebo administration with supportive psychotherapy, will 1) repair ATS-induced neural cell damage of the target brain regions, 2) improve cognitive deficits and normalize the relevant target neural circuits, and then 3) reduce ATS-taking behaviors in ATS-using adolescents.

Inclusion Criteria:

• Aged 14-40 years
• Amphetamine (or amphetamine-like) use disorder (DSM-IV-TR)
• Informed consent
• Seeking treatment

Exclusion Criteria:

• Major medical or neurological illnesses
• Psychiatric illnesses requiring hospitalization, prescription of psychotropic medications, or emergency psychiatric interventions
• Current and past diagnosis of a psychotic disorder, bipolar disorder, conduct disorder, or attention-deficit hyperactivity disorder
• Occasional ATS use (less than monthly use)
• IQ of 80 or lower
• Pregnancy or breastfeeding
• Clinically significant suicidal or homicidal ideation
• Substance use disorders (substances other than amphetamine or MA)